PTPI (petrospharma.com) Market Value to Book Value Ratio

Official company branding of Petros Pharmaceuticals Inc (PTPI)

The history of the market cap to book value ratio on the GURU.Markets chart shows that Petros Pharmaceuticals (PTPI) -0.01 is hitting a new level. This price action reflects the defensive nature of the sector, which remains independent of global crises. Growth is supported by plans to launch Stendra into OTC and the development of telemedicine, although poor management transparency and limited commercialization experience create certain risks for shareholders.

PTPI Petros Pharma: Market Value to Book Value in the range 07/04/2022 - 06/28/2025
Original product of Petros

When assessing the resilience of Petros Pharmaceuticals (PTPI) to market shocks, it is essential to analyze its net asset value. Business revenues are generated by the sale of urological drugs for men's health. This chart of the market capitalization to book value ratio reflects the premium investors pay for every dollar of equity. A high coefficient signals optimism but reduces the margin of safety, which determines the risk of a correction should the trend reverse.

Main competitors

Haleon plc - Market Capitalization to Book Value Ratio|KVUE (kenvue.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Market Cap to Net Assets Ratio|Market Value to Book Value TBPH (Theravance Biopharma Inc)|AQST: Market Value to Book Value Ratio|SCPH - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tectonic TECX|TNXP - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio BHST (BioHarvest)|Market-to-Book Ratio EXOZ|Oramed Pharmaceuticals (ORMP) - Market Value to Book Value Ratio|Market Value to Book Value ENTX (enterabio.com)|MindWalk Holdings Inc. (HYFT) - Market Value to Book Value Ratio|Market Capitalization to Net Assets ABVC BioPharma Inc. ABVC|CPIX (Cumberland Pharma) - Market Capitalization to Book Value Ratio|Quantum BioPharma Corp (QNTM) - Market-to-Book Ratio|FGEN - Market Cap to Net Assets Ratio|TELO (telomirpharma.com) - Market Cap to Book Value Multiple|RANI - Market Value to Book Value Ratio|Market Value to Book Value SNYR|Rallybio Corporation - Market Value to Book Value Ratio|Market-to-Book Ratio LEXX (lexariabioscience.com)|Market Value to Book Value Ratio PULM|PTHL - Market Capitalization to Book Value|Market Cap to Net Assets Ratio Aptorum (APM)|LYRA: Market Value to Book Value|Market Value to Book Value Ratio Impact BioMedical (IBO)|TNF Pharmaceuticals, Inc. (TNFA) - Market Capitalization to Net Assets|YCBD - Market Capitalization to Book Value Ratio|Market Value to Book Value painreform.com|Market Capitalization to Book Value Ratio CYTO|Market Capitalization to Book Value Ratio LIPO (Lipella Pharmaceuticals Inc)|Market Value to Book Value Ratio Optinose|Pieris Pharma - Market Value to Book Value|PROC: Market Value to Book Value Ratio|QLI - Market Cap to Net Assets Ratio|SLRN: Market Capitalization to Book Value Ratio|TFF Pharmaceuticals Inc. (TFFP) - Market Capitalization to Book Value Ratio